The role of cyclooxygenase-2 inhibitors (COX-2) is to reduce the gastrointestinal adverse effects and to improve the safety profile, but cyclooxygenase-2 inhibitors are associated with higher cost and cardiovascular complications, such as myocardial infarction and stroke [4,12,16]. This evidence concerns the gene PTGS2 and stroke disorder.